Results 31 to 40 of about 861 (122)

Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study. [PDF]

PLoS ONE, 2019
AIM:To evaluate the safety of 1.25mg and 2mg intravitreal ziv-aflibercept (IVZ) in Ghanaian eyes with choroido-retinal vascular diseases. DESIGN:Prospective, randomised, double blind, interventional study.
Imoro Zeba Braimah, Ernest Kenu, Kwesi N Amissah-Arthur, Stephen Akafo, Kwaku Oppong Kwarteng, Winfried M Amoaku   +5 more
doaj   +2 more sources

Intravitreal Ziv-Aflibercept in Treatment of Naïve Chronic Central Serous Chorioretinopathy Related Choroidal Neovascular Membrane [PDF]

Case Reports in Ophthalmological Medicine, 2017
Purpose. To study the effect and outcome of intravitreal Ziv-Aflibercept (IVZ) in treatment of Chronic Central Serous Chorioretinopathy (CSCR) related Choroidal Neovascular Membrane (CNVM). Methods.
Nishant Radke, Charudutt Kalamkar, Amrita Mukherjee, Snehal Radke   +3 more
doaj   +2 more sources

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC) [PDF]

Frontiers in Oncology, 2019
Background: The prognosis of patients with metastatic colorectal cancer (mCRC) is poor, especially after failure of initial systemic therapy. The VELOUR study showed modestly prolonged overall survival (OS) with ziv-aflibercept plus 5-fluorouracil ...
Wafik S. El-Deiry, Wafik S. El-Deiry, Arthur Winer, Michael Slifker, Stanford Taylor, Blythe J. S. Adamson, Neal J. Meropol, Eric A. Ross, Eric A. Ross   +8 more
doaj   +2 more sources

Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy. [PDF]

BMJ Case Rep, 2015
Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept
Videkar C, Kapoor A, Chhablani J, Narayanan R.   +3 more
europepmc   +4 more sources

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. [PDF]

Int J Retina Vitreous, 2016
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacological differences.
de Oliveira Dias JR, de Andrade GC, Novais EA, Farah ME, Rodrigues EB.   +4 more
europepmc   +4 more sources

The use of aflibercept (VEGF trap) in mitigating sulfur mustard-induced corneal neovascularization in a rabbit model

Toxicology Reports, 2023
Sulfur mustard (SM)-induced ocular injury is characterized by an acute inflammatory response that may become chronic or enter a latent phase with delayed pathology.
Ariel Gore, Tamar Kadar, Maayan Cohen, Hila Gutman, Rellie Gez, Shlomit Dachir, Vered Horwitz   +6 more
doaj   +1 more source

Iris metastasis as resistance mechanism to atezolizumab, carboplatin, and etoposide but responds to additional irinotecan and anlotinib in a small cell lung cancer patient

Thoracic Cancer, Volume 14, Issue 8, Page 779-782, March 2023., 2023
Small cell lung cancer patients presenting with metastasis of the iris are rare. Here, we report an extensive stage small cell lung cancer patient who presented with iris metastasis in the right eye and metastasis in the left adrenal gland as disease progression to first‐line chemotherapy plus atezolizumab.
Zhe Huang, Yongchang Zhang
wiley   +1 more source

The Inflation Reduction Act: A boon for the generic and biosimilar industry

Journal of Clinical Pharmacy and Therapeutics, Volume 47, Issue 11, Page 1738-1751, November 2022., 2022
The Inflation Reduction Act gives a significant boost to generics and biosimilars!Soon lowered out‐of‐pocket costBiosimilars promoted and adopted Abstract What is Known and Objective After more than a year of negotiation, a $740 billion climate and health care bill known as The Inflation Reduction Act (IRA) became law on 16 August 2022.
Sarfaraz K. Niazi
wiley   +1 more source

Ziv-aflibercept use in metastatic colorectal cancer.

J Adv Pract Oncol, 2013
Rodriguez M.
europepmc   +4 more sources

Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations

Clinical Pharmacology &Therapeutics, Volume 112, Issue 4, Page 782-790, October 2022., 2022
Patients with cancer and advanced hepatic impairment (HI) (i.e., moderate and severe impairment) are often excluded from first‐in‐patient, phase II, and phase III studies. Thus, dose recommendations for this subgroup of patients are often derived using a combination of dedicated phase I studies conducted in participants without cancer and a population ...
Derek Z. Yang, Ali Alhadab, Kourosh Parivar, Diane D. Wang, Mohamed Elmeliegy   +4 more
wiley   +1 more source